摘要
目的:研究薯蓣丸治疗强直性脊柱炎的临床疗效和安全性.方法:严格入组60例符合国际公认诊断标准、纳入标准、排除标准的强直性脊柱炎患者,用薯蓣丸口服治疗,疗程3个月,采用国际公认ASAS20、BASDAI50疗效评价标准,分别于治疗前、治疗1个月、治疗3个月后采用BASDAI评分、BASFI评分,测量枕墙距、指地距、schober试验,抽血查血清C-反应蛋白(CRP)、红细胞沉降率(ESR),以期系统客观评价薯蓣丸治疗强直性脊柱炎的临床疗效及安全性.结果:①BASDAI、BASFI评分.治疗前,患者对BASDAI、BASFI的评分较高,治疗后评分逐渐下降,治疗前后不同时间BASDAI、BASFI评分差异均有统计学意义(F=17.792,P=0.001;F=82.508,P=0.000).②主要体征:枕墙距、指地距、schober试验.治疗前,患者枕墙距、指地距测量数据较高,schober试验的测量数据较低,治疗后枕墙距、指地距测量数据逐渐减小,schober试验的测量数据逐渐增加,治疗前后不同时间枕墙距、指地距、schober试验测量数据的差异均有统计学意义(F=23.871,P=0.000;F=38.303,P=0.000;F=8.629,P=0.010).③实验室检查:血清C-反应蛋白(CRP)、红细胞沉降率(ESR).治疗前,患者CRP、ESR数据较高,治疗后CRP、ESR数据逐渐下降,治疗前后不同时间CRP、ESR数据的差异均有统计学意义(F=28.306,P=0.000;F=20.401,P=0.000).④在治疗1个月时达到ASAS20的人数为34例(56.67％),治疗3个月时达到ASAS20的人数为43例(71.67％);治疗1个月时达到BASDAI50的人数为26例(43.33％),治疗3个月时达到BASDAI50的人数为35例(58.33％).薯蓣丸能有效减轻缓解期AS患者的临床症状体征,在治疗3个月后可明显改善AS患者的BASDAI、BASFI、脊柱疼痛分数、功能指数、炎症分数等疗效指标,与治疗前比较有统计学差异.结论:薯蓣丸治疗强直性脊柱炎的临床效果显著,且无明显不良反应,提升了用药的安全性,值得广泛推广.
Abstract
Objective:To evaluate the efficacy and safety of Dioscorea pill in the treatment of ankylosing spondylitis.Method:Strictly into the group of 60 cases with internationally recognized diagnostic criteria,inclusion criteria,exclusion criteria of ankylosing spondylitis patients with Dioscorea pill treatment,a course of 3 months,the use of internationally recognized evaluation standard of curative effect of ASAS20,BASDAI50,respectively before treatment,treatment for 1 months,and 3 months after treatment by BASDAI score,the BASFI score,the pillow wall distance,finger to floor distance,Schober test,blood serum Creactive protein (CRP),erythrocyte sedimentation rate (ESR),with the clinical efficacy and safety of objective evaluation period system of Dioscorea pill in the treatment of ankylosing spondylitis.Results:The BASDAI and BASFI score.Before treatment,patients in the BASDAI,the BASFI score is higher,after treatment score decreased,before and after the treatment of different time of BASDAI and BASFI score difference was statistically significant (F=17.792,P=0.001;F=82.508,P=0.000);the main signs:the pillow wall distance,finger to floor distance,Schober test.Before treatment,patients with occipital wall distance,finger to floor distance measurement data is higher and the measured data of Schober test is low,after the treatment of occipital wall distance,finger to floor distance measurement data is gradually reduced,the measurement data of the Schober test increases gradually,before and after the treatment of different time pillow wall distance,finger to floor distance,difference of measurement data were Schober test statistical significance (F=23.871,P=0.000;F=38.303,P=0.000;F=8.629,P=0.010);third,laboratory examination,serum C-reactive protein (CRP),erythrocyte sedimentation rate (ESR).Before treatment,patients with higher CRP,ESR data,ESR data,CRP after treatment decreased gradually,before and after treatment of different time difference of CRP,ESR data were statistically significant (F=28.306,P=0.000;F=20.401,P=0.000);the number of the reaches ASAS20 in the treatment of 1 months in 34 cases(56.67％),treatment for 3 months when reached the ASAS20 number of 43 cases (71.67％);1 months treatment reach BASDAIS0 number for 26 cases (43.33％),3 months after treatment to BASDAIS0 for the number of 35cases (58.33％).Dioscorea pill can effectively reduce the remission of AS patients with clinical symptoms and signs,after 3 months of therapy can significantly improve AS in patients with BASDAI,BASFI,spinal pain scores,function index,such as inflammatory score index of curative effect,there is significant difference compared with those before treatment.Conclusion:The clinical effect of Dioscorea pill in the treatment of ankylosing spondylitis significantly,and no obvious adverse reactions,improve the drug safety,and is worthy of popularization.
国家科技期刊平台
NSTL
维普
万方数据